Brief: Amylyx Pharmaceuticals Announces First Participant Dosed In Pivotal Phase 3 Lucidity Trial Of Avexitide In Post-Bariatric Hypoglycemia
30/04/2025 12:16
April 30 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O: AMYLYX PHARMACEUTICALS ANNOUNCES FIRST PARTICIPANT DOSED IN PIVOTAL PHASE 3 LUCIDITY TRIAL OF AVEXITIDE IN POST-BARIATRIC HYPOGLYCEMIA AMYLYX PHARMACEUTICALS INC - LUCIDITY TRIAL RECRUITMENT EXPECTED TO COMPLETE IN 2025, WITH TOPLINE DATA IN FIRST HALF OF 2026 AMYLYX PHARMACEUTICALS INC - EXPECTS CASH RUNWAY THROUGH END OF 2026 Source text: ID:nBw27lFBca Further company coverage: AMLX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock